China Grand Pharmaceutical And Healthcare Holdings logo

512 - China Grand Pharmaceutical And Healthcare Holdings Share Price

HK$6.42 -0.0  -0.5%

Last Trade - 23/10/20

Sector
Healthcare
Size
Mid Cap
Market Cap £2.25bn
Enterprise Value £2.39bn
Revenue £617.4m
Position in Universe 444th / 6000
Bullish
Bearish
Unlock 512 Revenue
Momentum
Relative Strength (%)
1m -11.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
3,122 3,246 3,696 4,771 5,958 6,591 7,187 8,740 +16.1%
-12.9 -18.5 +50.3 +51.9 +38.2 +34.7 +8.69 +20.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, China Grand Pha.and Healthcare Hld. Ltd. revenues decreased 9% to HK$3.26B. Net income increased 31% to HK$718.5M. Revenues reflect People's Republic of China segment decrease of 11% to HK$2.56B, Europe segment decrease of 37% to HK$193.8M. Net income reflects Distribution Costs decrease of 24% to HK$955.5M (expense), Share of results of associates increase from HK$12.4M to HK$62.2M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 512
Graphical History

Revenue

512 Revenue Unlock 512 Revenue

Net Income

512 Net Income Unlock 512 Revenue

Normalised EPS

512 Normalised EPS Unlock 512 Revenue

PE Ratio Range

512 PE Ratio Range Unlock 512 Revenue

Dividend Yield Range

512 Dividend Yield Range Unlock 512 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
512 EPS Forecasts Unlock 512 Revenue
Profile Summary

China Grand Pharmaceutical and Healthcare Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture of pharmaceuticals. The main businesses of the Company include the research and development, manufacture and sales of pharmaceutical products, medical products, chemical products and healthcare products. The products of the Company include preparations, raw materials, medical devices, healthcare products, as well as agricultural and fine chemicals. Its products mainly focus on ophthalmic, cardiovascular and antibacterial, among others.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 18, 1995
Public Since December 19, 1995
No. of Shareholders: n/a
No. of Employees: 8,213
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng Composite Mid & SmallCap , Hang Seng Composite SmallCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 3,549,571,148
Free Float (0.0%)
Eligible for
ISAs
SIPPs
512 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 512
Upcoming Events for 512
Frequently Asked Questions for China Grand Pharmaceutical and Healthcare Holdings
What is the China Grand Pharmaceutical and Healthcare Holdings share price?

As of 23/10/20, shares in China Grand Pharmaceutical and Healthcare Holdings are trading at HK$6.42, giving the company a market capitalisation of £2.25bn. This share price information is delayed by 15 minutes.

How has the China Grand Pharmaceutical and Healthcare Holdings share price performed this year?

Shares in China Grand Pharmaceutical and Healthcare Holdings are currently trading at HK$6.42 and the price has moved by 43.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the China Grand Pharmaceutical and Healthcare Holdings price has moved by 43% over the past year.

What are the analyst and broker recommendations for China Grand Pharmaceutical and Healthcare Holdings?

Of the analysts with advisory recommendations for China Grand Pharmaceutical and Healthcare Holdings, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for China Grand Pharmaceutical and Healthcare Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will China Grand Pharmaceutical and Healthcare Holdings next release its financial results?

China Grand Pharmaceutical and Healthcare Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the China Grand Pharmaceutical and Healthcare Holdings dividend yield?

The China Grand Pharmaceutical and Healthcare Holdings dividend yield is 1.5% based on the trailing twelve month period.

Does China Grand Pharmaceutical and Healthcare Holdings pay a dividend?

Last year, China Grand Pharmaceutical and Healthcare Holdings paid a total dividend of 0.1, and it currently has a trailing dividend yield of 1.5%. Looking ahead, China Grand Pharmaceutical and Healthcare Holdings has not announced an ex-dividend date yet.

When does China Grand Pharmaceutical and Healthcare Holdings next pay dividends?

China Grand Pharmaceutical and Healthcare Holdings has yet to annouce their ex-dividend date. The historic dividend yield on China Grand Pharmaceutical and Healthcare Holdings shares is currently 1.5%.

How do I buy China Grand Pharmaceutical and Healthcare Holdings shares?

To buy shares in China Grand Pharmaceutical and Healthcare Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of China Grand Pharmaceutical and Healthcare Holdings?

Shares in China Grand Pharmaceutical and Healthcare Holdings are currently trading at HK$6.42, giving the company a market capitalisation of £2.25bn.

Where are China Grand Pharmaceutical and Healthcare Holdings shares listed? Where are China Grand Pharmaceutical and Healthcare Holdings shares listed?

Here are the trading details for China Grand Pharmaceutical and Healthcare Holdings:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 512
What kind of share is China Grand Pharmaceutical and Healthcare Holdings?

Based on an overall assessment of its quality, value and momentum, China Grand Pharmaceutical and Healthcare Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a China Grand Pharmaceutical and Healthcare Holdings share price forecast 2020?

Shares in China Grand Pharmaceutical and Healthcare Holdings are currently priced at HK$6.42. At that level they are trading at 55.76% discount to the analyst consensus target price of 0.00.

Analysts covering China Grand Pharmaceutical and Healthcare Holdings currently have a consensus Earnings Per Share (EPS) forecast of 0.377 for the next financial year.

How can I tell whether the China Grand Pharmaceutical and Healthcare Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China Grand Pharmaceutical and Healthcare Holdings. Over the past six months, the relative strength of its shares against the market has been 0.82%. At the current price of HK$6.42, shares in China Grand Pharmaceutical and Healthcare Holdings are trading at 10.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the China Grand Pharmaceutical and Healthcare Holdings PE Ratio?

The China Grand Pharmaceutical and Healthcare Holdings PE ratio based on its reported earnings over the past 12 months is 16.13. The shares are currently trading at HK$6.42.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of China Grand Pharmaceutical and Healthcare Holdings?

China Grand Pharmaceutical and Healthcare Holdings's management team is headed by:

Tosi Wan So - NID
Yan Shao - CEO
Chengwei Liu - CHM
Bo Hu - VCH
Geng Pei - NID
Tin Chung Foo - SEC
Guofan Xie - OTH
Xiaofeng Shi - OTH
Yonghua Feng - OTH
Bangguo Zhang - OTH
Zhanqi Niu - EDR
Yebi Hu - NID
Who are the major shareholders of China Grand Pharmaceutical and Healthcare Holdings?

Here are the top five shareholders of China Grand Pharmaceutical and Healthcare Holdings based on the size of their shareholding:

Outwit Investments Ltd Corporation
Percentage owned: 47.1% (1.67bn shares)
CDH Investments Private Equity
Percentage owned: 10.05% (356.6m shares)
Shanghai China Grand Asset Finance Investment Management Co Corporation
Percentage owned: 8.06% (286.0m shares)
GL Saino Investment Ltd Corporation
Percentage owned: 5.07% (180.0m shares)
Oasis Management Company Ltd. Investment Advisor
Percentage owned: 1.36% (46.1m shares)
Similar to 512
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.